Stay updated on Intratumoral SD-101 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.

Latest updates to the Intratumoral SD-101 + Pembrolizumab Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new identifiers and collaborators related to the SYNERGY-001 trial for metastatic melanoma, while extensive details about the trial's design and inclusion/exclusion criteria have been removed.SummaryDifference45%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.7%
Stay in the know with updates to Intratumoral SD-101 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.